Reports Q4 revenue $181.90M, consensus $ $177.53M .ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies, with expectations for one oncology program to enter the clinic this year. In 2023, Modex secured two collaborations including one with Merck to develop MDX-2201, its vaccine for Epstein-Barr virus, and another with BARDA to develop novel multispecific antibodies against viral infectious disease threats.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPK:
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
- Largest borrow rate increases among liquid names
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
- OPK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Opko Health Board Member Alexis Borisy to Depart
